StocksInsight

DOC Stock vs the S&P 500: Returns, Risk and Crash History

Healthpeak Properties, Inc., real estate (market value $14.1 billion), an S&P 500 member: how it compared with the S&P 500, how it behaved in every crash since 2008, its risk‑adjusted returns and what analysts said. Returns to Oct 30, 2026; analyst data as of Nov 16, 2026.

Published Updated 4 min readHow we research

Key takeaways

  • DOC returned −21.9% over the 5 years to Oct 30, 2026 versus +75.9% for the S&P 500: it lagged the index.
  • Its 5-year Sharpe ratio was −0.17 against 0.58 for the S&P 500.
  • Its deepest crisis drawdown was −61.7% in the global financial crisis (2007–09) (S&P 500: −56.5%).
  • Five‑year volatility was 26.5% and beta 1.03.
  • 18 analysts rated it in the past year; 31% of their latest calls were Buy.
  • DOC beat earnings estimates in 7 of its last 12 reports; the stock moved 5.0% on average, up or down, around each report.

What do the best‑ranked analysts on DOC say now? See it in Exent Gems →

Did DOC beat the S&P 500?

Over the 5 years to Oct 30, 2026, Healthpeak Properties, Inc. (DOC) returned −21.9% including dividends, versus +75.9% for the S&P 500 (SPY). It lagged the index by 97.8 percentage points, or −4.8% a year against +12.0%.

PeriodDOCS&P 500DOC per yearS&P 500 per yearResult
1 year+13.2%+12.0%+13.2%+12.0%Beat
3 years+51.1%+87.4%+14.7%+23.3%Lagged
5 years−21.9%+75.9%−4.8%+12.0%Lagged
10 years+21.4%+316.3%+2.0%+15.3%Lagged
  • 1 year
    DOC
    +13.2%
    S&P 500
    +12.0%
    DOC per year
    +13.2%
    S&P 500 per year
    +12.0%
    Result
    Beat
  • 3 years
    DOC
    +51.1%
    S&P 500
    +87.4%
    DOC per year
    +14.7%
    S&P 500 per year
    +23.3%
    Result
    Lagged
  • 5 years
    DOC
    −21.9%
    S&P 500
    +75.9%
    DOC per year
    −4.8%
    S&P 500 per year
    +12.0%
    Result
    Lagged
  • 10 years
    DOC
    +21.4%
    S&P 500
    +316.3%
    DOC per year
    +2.0%
    S&P 500 per year
    +15.3%
    Result
    Lagged

Total return with dividends reinvested, from month-end prices to Oct 30, 2026. Beating the index on raw return is only half the story: the next section adjusts for the risk taken. See also how to beat the S&P 500.

DOC is in the S&P 500 (members as of Oct 20, 2026); the list shows every member’s return against the index.

What Wall Street analysts say about DOC

In the 12 months to 30 days ago, 18 analysts published 132 ratings on DOC. Their latest calls were 31% Buy, 69% Hold and 0% Sell. 4 of them rank 4★ or higher in Exent’s analyst scoring, which is based on each analyst’s past price‑target hit rate and returns.

The consensus 12‑month price target was $22.00 (range $20.00–$24.00), +13.8% from the last price. Remember that the average analyst’s target is hit only about half the time: how accurate are price targets?

Top‑ranked analyst coveringFirmStarsPrice‑target hit rate
??????4.7★53.1%
??????4.7★35.0%
??????4.7★34.9%
??????4.4★49.6%

Ratings are shown with a 30‑day delay. Who the top‑ranked analysts on DOC are, their live calls and the median target of only the top‑rated analysts are in Exent Gems.

The average analyst’s target is reached about 53.0% of the time; Exent Gems is built on the top 50 of Exent’s ranking,where some reached 90% or more over the last two years. Unlock the top 50 analysts.

DOC returns by year vs the S&P 500

DOC beat the S&P 500 in 2 of the 9 full calendar years shown.

YearDOCS&P 500Difference
2026 (to Oct 30, 2026)+24.9%+11.7%+13.2%
2025−15.2%+17.7%−32.9%
2024+10.0%+24.9%−14.9%
2023−12.6%+26.2%−38.8%
2022−25.2%−18.2%−7.0%
2021+27.3%+28.7%−1.4%
2020−4.5%+18.3%−22.8%
2019+33.1%+31.2%+1.9%
2018+17.9%−4.6%+22.5%
2017−4.8%+21.7%−26.5%

DOC risk-adjusted returns: Sharpe, Sortino and volatility

Over 5 years, DOC had a Sharpe ratio of −0.17 against 0.58 for the S&P 500, so it earned less return per unit of risk than the index. Its annualized volatility was 28.2% and its beta 1.03: it tended to move about 1.0× as much as the market.

MetricDOCS&P 500
Annual return−4.8%+12.0%
Volatility (annualized)28.2%15.5%
Sharpe ratio−0.170.58
Sortino ratio−0.240.91
Max drawdown (month-end)−49.6%−23.9%
Beta to the S&P 5001.031.00

Sharpe divides return above cash by total volatility; Sortino counts only downside volatility. Both use monthly returns and the 1–3 month T‑bill ETF (BIL) as the risk‑free rate.

How DOC behaved in past crashes

DOC’s deepest fall in the crises below was −61.7% in the global financial crisis (2007–09), against −56.5% for the S&P 500. The last column turns that into money: what a $100,000 position would have lost from peak to trough.

CrisisDOCS&P 500Loss on $100,000
Global financial crisis (2007–09)−61.7%−56.5%−$61,700
2018 trade-war selloff−11.4%−20.2%−$11,450
COVID crash (Feb–Mar 2020)−46.5%−34.1%−$46,500
2022 inflation bear market−41.0%−25.4%−$41,050
2025 tariff selloff−13.0%−19.0%−$12,970
WindowDOC max drawdown
Last 1 year−18.1%
Last 3 years−26.0%
Last 5 years−50.7%
Last 10 years−61.4%

Peak‑to‑trough declines from daily prices inside each crisis window. A crash replay does not predict the next crisis; it shows how much room a holding needs. Run the same replay on a whole portfolio with the crash test.

What moves with DOC, and what doesn’t

Correlation runs from −1 (moves opposite) to +1 (moves in lockstep). Over the last 60 months of monthly returns, DOC’s correlation with the S&P 500 was 0.57, with the Nasdaq‑100 0.42, with long Treasuries (TLT) 0.51 and with gold (GLD) 0.21.

Adding a 5% DOC position to an S&P 500 portfolio would have moved its 5‑year volatility from 15.5% to 15.5%.

Least correlated large capsCorrelationMost correlated large capsCorrelation
PLTR−0.07MMM0.64
CME−0.03PLD0.61
SNPS0.00MS0.61
INTU0.01DUK0.57
NET0.03USB0.57

Holdings that are highly correlated behave like one position in a selloff. See how to find hidden overlap.

Latest DOC upgrades, downgrades and price‑target changes

DateRating and targetAnalyst
Oct 19Target cut
Hold
Target $19, was $22
John Kilichowski
Wells Fargo
Oct 13Target cut
Hold
Target $20, was $21.50
Michael Goldsmith
UBS
Oct 13Target cut
Hold
Target $21, was $24
Richard Hightower
Barclays
Sep 21Target cut
Hold
Target $22, was $23
James Kammert
Evercore ISI

Named analysts’ rating and price‑target changes on DOC in the 5 weeks to Oct 20, 2026, shown 30 days after publication (the free analysts’ calls 3 days after). The top‑ranked analysts’ calls are in Exent Gems. See all of the latest analyst upgrades and downgrades.

Do analysts get DOC right?

Of the 252 analyst price targets on DOC set from 2019 until a year ago, 46.4% were reached within 12 months (data to Oct 20, 2026), 22.2 points below the 68.6% hit rate of the median stock in Exent’s study of 794 stocks. Targets that were reached took a median of 81 days. The median target sat 13.2% above the share price on the day it was set.

Where analysts said DOC would be by now: a year ago, 8 analysts had a price target on DOC, and the median of their latest targets was $20.00. On Oct 20, 2026 DOC closed at $18.76, 6.2% below it.

46.4%of targets reached within 12 monthsMedian stock: 68.6%
81 daysmedian time to reach a target
−6.2%price now vs the median target set a year ago
AfterCallsMove on the call3 months vs S&P 500
Upgrades of DOC14+0.9%−1.7%
Upgrades, all stocks11,514+2.5%+3.4%
Downgrades of DOC11−0.5%−2.2%
Downgrades, all stocks10,700−3.0%−1.6%

The move on the call runs from the close before the rating change to the close after it; the last column is the stock’s return minus the S&P 500’s over the next three months. Averages of rating changes on DOC through Sep 15, 2026; analysts are not named here. Do analyst upgrades move stocks?

How DOC moves after earnings

DOC beat the consensus earnings‑per‑share estimate in 7 of its last 12 quarterly reports, through the one on Aug 4, 2026, and the revenue estimate in 10 of 12. From the close before each report to the close after it, the stock moved 5.0% on average, up or down, against 6.8% for the average report across the 1,002 US stocks Exent tracks. It rose after 5 of the 12 reports. In 4 of the 7 beats the stock still fell.

7/12earnings beats
±5.0%average move per report
5/12reports followed by a rise
ReportEPS vs estimateRevenue vs estimateStock move
Aug 4, 2026$0.08 vs $0.03+3.3%+0.7%
May 5, 2026$0.28 vs $0.05+6.4%+19.7%
Feb 2, 2026$0.16 vs $0.45+1.9%−4.6%
Oct 23, 2025−$0.17 vs $0.06+0.5%+0.7%
Jul 24, 2025$0.05 vs $0.06−1.6%−7.6%
Apr 24, 2025$0.06 vs $0.05+2.9%−5.3%
Feb 3, 2025$0.01 vs $0.05+1.3%−2.9%
Oct 24, 2024$0.12 vs $0.07+2.6%−3.6%

Reported earnings per share against the consensus estimate, revenue surprise in percent, and the stock’s price change over the two sessions around the report. How stocks move after earnings

Where DOC’s revenue comes from

In fiscal 2025 (the year to Dec 31, 2025), DOC’s largest reported region was Outpatient Medical Buildings, with 46.5% of its $2.7 billion revenue. By region: Outpatient Medical Buildings 46.5%; Lab 31.4%; Senior Housing 22.1%.

By business, the largest segment was Outpatient Medical Buildings, with 46.5% of $2.7 billion revenue.

  • Outpatient Medical Buildings46.5%
  • Lab31.4%
  • Senior Housing22.1%
SegmentRevenueShareGrowth
Outpatient Medical Buildings$1.3 billion46.5%—
Lab$860.0 million31.4%—
Senior Housing$604.0 million22.1%—

From DOC’s annual filings; segment growth compares fiscal 2025 with the year before. Regions are as each company reports them, so one company’s “Asia Pacific” is not another’s. China counts the regions a company reports as China, Greater China or Hong Kong; a separately reported Taiwan is not counted. Which S&P 500 companies depend most on China?

Members of Congress who traded DOC

As of Oct 20, 2026, 6 members of Congress had disclosed 9 trades in DOC (4 buys and 5 sales) in STOCK Act disclosures filed with the House and Senate. The latest public trade is dated Mar 27, 2026.

Trade dateMemberTypeAmount
Mar 27, 2026Alan ArmstrongBuy$1,001–$15,000
Jan 9, 2026Gilbert CisnerosBuy$1,001–$15,000
Aug 4, 2025Lisa McClainSale$1,001–$15,000
Jun 17, 2025Lisa McClainBuy$1,001–$15,000
May 15, 2025Rob BresnahanSale$1,001–$15,000
Apr 1, 2025Julie JohnsonSale$1,001–$15,000
Dec 12, 2022Christopher JacobsBuy$1,001–$15,000
Nov 8, 2022Christopher JacobsSale$1,001–$15,000
Jul 18, 2022Christopher JacobsSale$1,001–$15,000

Amounts are the ranges members report, not exact values. The STOCK Act gives members up to 45 days to disclose a trade, so trades appear weeks after they are made. See every member’s disclosed trades

Are DOC insiders buying or selling?

In the 12 months to Oct 20, 2026, DOC insiders made no open‑market purchases and 1 sale worth $213,740, according to SEC Form 4 filings. The last open‑market purchase on record was on Aug 6, 2025.

After the 60 insider purchases of $10,000 or more since 2012, DOC lagged the S&P 500 by an average of 11.5 percentage points over the next 12 months; 25% of them were followed by a beat. Across all 17,865 insider purchases in Exent’s study, the average was +17.2% and the median +1.0% against the index.

Q3 ’24
Q4 ’24
Q1 ’25
Q2 ’25
Q3 ’25
Q4 ’25
Q1 ’26
Q2 ’26
DateInsiderRoleValue
Aug 6, 2025Thomas John TDirector$24,730
Aug 4, 2025Brinker Scott MDirector, officer: President and CEO$25,077
Jul 31, 2025Brinker Scott MDirector, officer: President and CEO$49,986
Jul 28, 2025Brinker Scott MDirector, officer: President and CEO$49,990
May 28, 2025Thompson Tommy GDirector$99,769

The table lists the latest open‑market purchases on record, leaving out the last 30 days. The chart counts Form 4 purchases and sales by calendar quarter. Purchases are open‑market buys; sales include planned sales under 10b5‑1 trading plans. Do insider buys beat the market?

How much of DOC is sold short?

As of the Sep 30, 2026 settlement date, 3.40% of DOC’s float was sold short: 23.3 million shares, or 3.8 days of average trading volume to cover. A year earlier (Oct 15, 2025) it was 2.27%. The median across the 997 US stocks Exent tracks was 4.77%, so DOC is less heavily shorted than most.

  • Apr 30, 20264.68%
  • May 29, 20264.05%
  • Jun 30, 20263.95%
  • Jul 31, 20263.55%
  • Aug 31, 20263.52%
  • Sep 30, 20263.40%

From FINRA short‑interest reports, filed twice a month; the bars show the short share of the float at each month‑end. Days to cover divides the shares short by the average daily volume. The most shorted stocks

How many institutions own DOC?

At the end of Q2 2026 (Jun 30, 2026), 776 institutions reported holding DOC in 13F filings, the same as a quarter earlier and up from 743 a year earlier. Their reported holdings add up to 97.5% of DOC’s shares. In the quarter 339 institutions added to their positions and 324 cut them.

77613F holders
102new positions
100positions closed
97.5%of shares held by 13F filers

Investment managers with over $100 million in US equities file 13F reports within 45 days of each quarter end, so this is the latest complete quarter. Holdings can add up to more than 100% when shares are lent and counted twice. Which stocks institutions are buying and selling

Is DOC diluting shareholders?

DOC’s diluted share count rose 31.1% over the five fiscal years to fiscal 2025 and rose 2.9% in fiscal 2025 alone. Each share now owns a smaller slice of the company. The median change across the 1,005 US stocks Exent tracks was −0.1%.

Stock‑based compensation was $14.4 million in fiscal 2025, 0.5% of revenue. DOC spent $97.1 million buying back shares, a buyback yield of 0.69% of its market value; stock pay equaled 14.8% of the buybacks.

+2.9%share count, 1 year
+31.1%share count, 5 years
0.5%stock pay as % of revenue
0.69%buyback yield

Weighted‑average diluted shares from DOC’s annual income statements; stock‑based compensation and buybacks from its cash‑flow statement. Stock dilution and stock‑based compensation, explained

DOC financial health scores

In Exent’s Oct 20, 2026 snapshot, DOC’s Piotroski F‑score was 7 out of 9; 40% of scored stocks reach 7 or more. The Altman Z‑score is not meaningful for real estate companies, so it is left out.

The Altman Z‑score combines five balance‑sheet and earnings ratios into one bankruptcy‑risk score: below 1.81 is the distress zone, 1.81–2.99 grey, above 2.99 safe. It is not meaningful for banks, insurers and REITs. The Piotroski F‑score counts nine yes/no tests of profitability, leverage and efficiency; 8–9 is strong, 0–2 weak. Both come from the latest annual statements. Which stocks have the highest bankruptcy risk?

What DOC talks about on earnings calls

On its latest earnings call (Aug 5, 2026), DOC’s executives and analysts did not mention AI, against 0 on the call before (May 6, 2026); the average across 455 S&P 500 calls that quarter was 12.9. After AI, the most mentioned topic was ai agents (1). Tariffs and recession did not come up.

MentionsAug ’26May ’26Feb ’26Oct ’25
AI0037
AI agents1000
Data centers0000
Tariffs0001
China0000
Recession0000
  • AI
    Aug ’26
    0
    May ’26
    0
    Feb ’26
    3
    Oct ’25
    7
  • AI agents
    Aug ’26
    1
    May ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Data centers
    Aug ’26
    0
    May ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Tariffs
    Aug ’26
    0
    May ’26
    0
    Feb ’26
    0
    Oct ’25
    1
  • China
    Aug ’26
    0
    May ’26
    0
    Feb ’26
    0
    Oct ’25
    0
  • Recession
    Aug ’26
    0
    May ’26
    0
    Feb ’26
    0
    Oct ’25
    0

Word counts in the full transcript of each call, prepared remarks and Q&A, newest first. “AI” also counts generative AI and large language models; “AI agents” counts agentic AI. Which companies talk most about AI?

Which ETFs hold DOC?

As of Oct 20, 2026, 39 of the 304 ETFs Exent tracks held DOC. Its largest weight is in BKGI (Bny Mellon Global Infrastructure Income ETF), at 6.59% of the fund.

ETFFundWeight of DOC
BKGIBny Mellon Global Infrastructure Income ETF6.59%
SCHHSchwab U.S. REIT ETF0.94%
VNQVanguard Real Estate Index Fund ETF Shares0.92%
FDVVFidelity High Dividend ETF0.87%
VBRVanguard Small-Cap Value Index Fund ETF Shares0.31%
SCHMSchwab U.S. Mid-Cap ETF0.27%
CLSEConvergence Long/Short Equity ETF0.26%
RSPInvesco S&P 500 Equal Weight ETF0.18%

Owning several of these funds stacks the same position. How much do VOO, QQQ and VTI overlap?

How much is DOC’s CEO paid?

Scott M. Brinker, DOC’s President and Chief Executive Officer, received total pay of $10.1 million for fiscal 2025, up 19.0% from $8.5 million for fiscal 2024, according to the company’s proxy statement filed with the SEC on Mar 12, 2026. 72% of it came as stock and option awards, valued when they were granted rather than when they pay out. The median CEO pay across the 378 S&P 500 companies Exent tracks was $17.2 million, so DOC’s CEO earned less than most.

Pay componentAmountShare of total
Salary$825,0008.2%
Stock and option awards$7.2 million71.6%
Incentive plan (cash)$2.0 million19.7%
Other$53,1500.5%
Other top executivesRoleTotal pay, 2025
Kelvin O. MosesChief Financial Officer$3.6 million
Thomas M. KlaritchFormer Chief Operating Officer$2.9 million
Adam G. MabryChief Investment Officer$2.9 million
Scott R. BohnChief Development Officer and Head of Lab$2.6 million

Figures from the summary compensation table of the proxy statement; awards count at their grant‑date value, so one large multi‑year grant can make a single year stand out. CEO pay across the S&P 500

The right benchmark for DOC

Exent matches every holding to the index with the most similar risk. For DOC that is MDY. Comparing a holding with an index that carries very different risk makes good results look bad and risky ones look clever. Read why the S&P 500 is the wrong benchmark for most portfolios.

Other real estate stocks

TickerName5‑year returnVolatility (5y)
WELLWelltower Inc.+228.9%23.6%
PLDPrologis, Inc.+2.3%26.9%
EQIXEquinix, Inc.+33.8%27.9%
SUISun Communities, Inc.−30.9%24.8%
NLYAnnaly Capital Management, Inc.+7.2%25.5%
REGRegency Centers Corporation+29.7%22.4%
OHIOmega Healthcare Investors, Inc.+137.2%24.1%
MAAMid-America Apartment Communities, Inc.−30.2%22.1%

Data and methodology

Returns are total returns from month‑end adjusted closing prices (dividends reinvested) through Oct 30, 2026. Crisis drawdowns and trailing maximum drawdowns use daily prices. Analyst coverage counts ratings published in the last 12 months, shown with a 30‑day delay. Full method: Exent methodology.

Company data as of Oct 20, 2026. The move around an earnings report runs from the close before it to the close after it; a price target counts as hit when the stock closed at or beyond it within 12 months (Exent analyst data). Revenue by region and segment, share counts and executive pay come from company filings; insider trades from SEC Form 4, short interest from FINRA, institutional ownership from 13F filings, Congress trades from STOCK Act disclosures filed with the House and Senate, federal contracts from USAspending.gov. Filings from the last 30 days are shown as counts only.

Past performance does not guarantee future results. Historical figures are calculated by Exent from market data and are for education only; they are not investment advice or a recommendation to buy or sell any security.

Check DOC with Exent Gems

Wall Street’s average DOC price target is 13.8% above the latest share price. See what the best‑ranked analysts on DOC say now in Exent Gems.

  1. Exent ranks Wall Street analysts by their past price‑target hit rate and returns, and keeps the best‑ranked few.
  2. Gems shows who the top‑ranked analysts covering DOC are, their live calls and the median target of only the top‑rated analysts.
  3. Gems flags the stocks where several top‑ranked analysts agree: a starting point for your own research, not a promise.

Exent is our product. Educational content, not investment advice.

Frequently asked questions

No. DOC returned +21.4% (+2.0% a year) over the 10 years to Oct 30, 2026, versus +316.3% (+15.3% a year) for the S&P 500, including dividends.

Yes. As of Oct 20, 2026, DOC (Healthpeak Properties, Inc.) is one of the 503 stocks in the S&P 500.

DOC fell −61.7% from peak to trough during the global financial crisis (2007–09), versus −56.5% for the S&P 500.

DOC fell −46.5% from peak to trough during the covid crash (feb–mar 2020), versus −34.1% for the S&P 500.

DOC fell −41.0% from peak to trough during the 2022 inflation bear market, versus −25.4% for the S&P 500.

Over the 5 years to Oct 30, 2026, DOC’s Sharpe ratio was −0.17 and its Sortino ratio −0.24, versus 0.58 and 0.91 for the S&P 500.

DOC’s 5‑year annualized volatility was 26.5%, higher than the S&P 500’s 17.0%, with a beta of 1.03.

Among large US stocks, the lowest correlations with DOC over the last 60 months were PLTR (−0.07), CME (−0.03), SNPS (0.00). Its correlation with long Treasuries (TLT) was 0.51 and with gold (GLD) 0.21.

DOC beat the consensus earnings-per-share estimate in 7 of its last 12 quarterly reports through Aug 4, 2026, and the revenue estimate in 10 of 12. The stock moved 5.0% on average, up or down, from the close before each report to the close after it.

Scott M. Brinker, DOC’s President and Chief Executive Officer, received $10.1 million in total pay for fiscal 2025, including a $825,000 salary and $7.2 million in stock and option awards valued at grant, according to the proxy statement filed with the SEC on Mar 12, 2026. The median S&P 500 CEO received $17.2 million.

Yes. As of Oct 20, 2026, 6 members of Congress had disclosed 9 trades in DOC (4 buys and 5 sales) in STOCK Act disclosures filed with the House and Senate.

As of the Sep 30, 2026 settlement date, 3.40% of DOC’s float was sold short (23.3 million shares, 3.8 days to cover), according to FINRA short-interest reports. A year earlier it was 2.27%.

Yes. DOC’s diluted share count rose 31.1% over the five fiscal years to fiscal 2025 and rose 2.9% in the latest year. Stock-based compensation was 0.5% of revenue, and buybacks totaled $97.1 million.

What do the best‑ranked analysts say on DOC now?

Exent ranks Wall Street analysts by their track record. Gems shows who the top‑ranked analysts on DOC are, their latest calls and the stocks where several of them agree.

See this week’s GemsLimited offer$1.95 for full access· full access

Educational content, not investment advice. Examples are illustrative; past performance does not guarantee future results.

DISCLAIMER: Exent AI is an informational research platform and does not provide investment advice, financial advice, or act as an investment adviser, broker-dealer, or fiduciary. All content, analytics, and model outputs are provided for educational and informational purposes only and should not be relied upon as a recommendation to buy, sell, or hold any financial instrument. Investing involves risk, including the possible loss of principal. Exent AI does not execute trades, hold customer funds, or provide brokerage services. Past performance and hypothetical results are not indicative of future results. Third-party data and AI-generated outputs may be incomplete or inaccurate.